• SELECT SITE CURRENCY
Select a currency for use throughout the site
The Future of Contract Manufacturing - Market Forecasts to 2015 and Key Trends
GBI Research, December 2009, Pages: 67
“The Future of Contract Manufacturing - Market Forecasts to 2015 and Key Trends”. The report provides key data, information and analysis of the global contract manufacturing market. Further the report provides comprehensive information on the different service models present in the industry, key trends affecting contract manufacturing organizations and analytical content on the market dynamics. The report also reviews the competitive landscape, mergers and acquisitions, strategic partnerships and service agreements.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
The scope of this report includes:
- Annualized market data for the global contract manufacturing market from 2000 to 2008, with forecasts to 2015
- Data and analysis on the global contract manufacturing market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Key drivers and restraints that have a significant impact on the market
- Information on the cost, developmental and regulatory issues facing contract manufacturing.
- Competitive landscape of global contract manufacturing market including benchmarking of top companies. The key companies studied in this report are Jubilent Biosciences, Piramal Healthcare, Lonza Biologics, Catalant, DSM, Sandoz and Boehringer Ingelheim.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global contract manufacturing market.
Reasons to buy
The report will aid business development and marketing executives strategizing their product launches:
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Identify key players best positioned to take advantage of the emerging market opportunities
- Overcome the regulatory hurdles in the contract manufacturing outsourcing market
- Exploit in-licensing and out-licensing opportunities by identifying key trends that might probably fill their portfolio gaps.
- Make informed decisions related to the M&A activities in the contract manufacturing outsourcing market
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.1 GBI Research Report Guidance
3 Industry Overview
3.1 CMO Industry Structure
3.2 Types of Outsourcing
3.3 Applications of CMOs
3.3.1 Primary Development
3.3.2 Pre-Formulation Studies and Formulation Development
3.3.3 Dosage Creation
3.3.4 Primary and Secondary Manufacturing
4 Global CMO Market – Market Characterization
4.1 Market Forecasts
5 Geographical Landscape
5.2 Emerging Markets
5.2.1 The Indian CMO Market
5.2.2 The Chinese CMO Market
6 Market Drivers and Restraints
6.1 Market Drivers
6.1.1 Increased Utilization of Biologics for Disease Therapy
6.1.2 Increase in Demand for Generics
6.1.3 Providing End-To-End Solutions
6.1.4 Increase in Number of Government Sanctions and Policies Favoring CMOs
6.2 Market Restraints
6.2.1 Complex Cost Structures in Outsourcing
6.2.2 The Complex Manufacturing Procedures for Biopharmaceuticals
6.2.3 Reduced number of Drug Approvals
7 Regulatory Framework
7.2 FDA Guidelines
7.2.1 Organization and Personnel
7.2.2 Building and Facilities
7.2.3 Process Equipment
7.2.4 Control of Raw Materials
7.2.5 Production and Process Controls
7.2.6 Packaging and Labeling
7.2.7 Holding and Distribution
7.2.8 Key Changes in FDA Guidelines
7.3 EMEA Guidelines
7.3.1 Quality Management
7.3.2 Production Activities
7.3.3 Buildings and Facilities
7.3.4 Process Equipment
7.3.5 Materials Management
7.3.6 Packaging and labeling
7.3.7 Key Changes in EMEA Guidelines
8 Key Aspects of the CMO Industry
8.1 The Need for Outsourcing
8.1.1 Change in Pharmaceutical Industry Structure
8.1.2 Key Benefits of Outsourcing
8.2 Key Outsourcing Models
8.2.1 Mixed Sourcing Model
8.2.2 Sale Leaseback Model
8.3 Management of CMO Manufacturing
8.3.1 Choosing the Right CMO
8.3.2 Key Steps Involved in Executing Projects
8.3.3 Risk Assessment
9 Key CMO Participants
9.3 Piramal Healthcare
9.4 Jubilant Organosys
9.5 Royal DSM N.V.
9.10 Boehringer Ingelheim
10 Strategic Consolidations within the Global CMO Market
10.2.1 The key agreements that have taken place since 2008 have been discussed below.
10.3 Mergers and Collaborations
10.3.1 The notable mergers and collaborations that have taken place since 2008 are discussed below.
10.4.1 The key acquisition that have taken place since 2008 are discussed below.
11.1 Market Definitions
11.3 Research Methodology
11.3.2 Secondary Research
11.3.3 Primary Research
11.3.4 Expert Panel Validation
11.4 Contact Us
List of Tables:
Table 1: CMO Market, India, Key CMO Agreements, 2005-2007
Table 2: CMO Market, China, Leading Biopharmaceuticals Companies in China, 2008
Table 3: CMO Market, Global, Major Drug Patent Expirations, 2008-2015
List of Figures:
Figure 1: CMO Market, Global, Basic Services Provided, 2008
Figure 2: CMO Market, Global, CMO Industry Structure, 2008
Figure 3: CMO Market, Global, Key Applications of CMOs, 2008
Figure 4: CMO Market, Global, Key Steps in API Manufacturing, 2008
Figure 5: CMO Market, Global, Revenue Forecasts, 2006-2015
Figure 6: CMO Market, Global, Market Share by Services Provided, 2008
Figure 7: CMO Market, Global, Key Geographical Trends, 2008
Figure 8: CMO Market, Global, Market Share by Geographic Area, 2008
Figure 9: CMO Market, Global, Percentage Split of Manufacturing Portfolio By Geographic Regions, 2008
Figure 10: CMO Market, India, Key Factors Driving Outsourcing, 2008
Figure 11: CMO Market, India, Revenue Forecasts, 2006-2015
Figure 12: CMO Market, India, Key Concerns for Outsourcing, 2008
Figure 13: CMO Market, China, Key Factors Driving Outsourcing, 2008
Figure 14: CMO Market. Global, Assessment of API Manufacturing by Region, 2007
Figure 15: CMO Market, China, Revenue Forecast ($bn), 2006-2015
Figure 16: CMO Market, Global, Key Market Drivers and Restraints, 2008
Figure 17: CMO Market, Global, Forecasts for Sales Between Conventional Drugs and Biologics, 2006-2015
Figure 18: CMO Market, Global, Biologic Drugs Under Development, 2008
Figure 19: CMO Market, Global, CMOs Providing Overall Pharmaceutical Solutions, 2008
Figure 20: CMO Market, Global, FDA Drug Approvals of NDAs and NBEs, 2000-2008
Figure 21: CMO Market, Global, EMEA Guidelines for API Production, 2008
Figure 22: CMO Market, Global, Market Lifecycle, 2008
Figure 23: CMO Market, Global, Fragmentation of the Pharmaceutical Industry, 2008
Figure 24: CMO Market, Global, Key Benefits of Outsourcing, 2008
Figure 25: CMO Market, Global, Mixed Source Model, 2008
Figure 26: CMO Market, Global, Sale-Leaseback Model, 2008
Figure 27: CMO Market, Global, Key Points While Considering CMOs, 2008
Figure 28: CMO Market, Global, Responsibilities of Sponsor and CMO on Various Aspects of Manufacturing, 2008
Figure 29: CMO Market, Global, Key Points While Considering CMOs, 2008
Figure 30: CMO Market, Global, Company Profiles - Catalent, 2008
Figure 31: CMO Market, Global, Company Profiles – Lonza, 2008
Figure 32: CMO Market, Global, Company Profiles – Piramal Healthcare, 2008
Figure 33: CMO Market, Global, Company Profiles – Jubilant Organosys , 2008
Figure 34: CMO Market, Global, Company Profiles – DSM, 2008
Figure 35: CMO Market, Global, Company Profiles – Evonik, 2008
Figure 36: CMO Market, Global, Company Profiles – Patheon, 2008
Figure 37: CMO Market, Global, Company Profiles – Fareva, 2008
Figure 38: CMO Market, Global, Company Profiles – Cambrex, 2008
Figure 39: CMO Market, Global, Company Profiles – Boehringer Ingelheim, 2008
Figure 40: CMO Market, Global, Strategic Consolidations Split by Agreements Type and Geography, 2008
Figure 41: CMO Market, Global, Strategic Consolidations Split by Agreements Type and Geography, 2008
Figure 42: GBI Research Methodology
“The Future of Contract Manufacturing – Market Forecasts to 2015 and Key Trends ” provides an essential source of data and analysis on the global CMO market with coverage on the market landscape, key market trends, market drivers and restraints. The report identifies the key trends shaping and driving the dynamism in the global CMO market. The report also provides an insight in to the prevalent competitive landscape with key company profiles.
The Global CMO Market is Forecast to Show Steady Growth over the Forecast Period
The report suggests that the global contract manufacturing outsourcing (CMO) market set to grow steadily due to increased outsourcing of Pharmaceutical production for Western Pharmaceutical manufacturers to Asian Countries. The global CMO market was valued at $21 billion in 2008. This market grew at around 9.5% over 2007 when the market was approximately $19.5 billion. The major factor driving this market is the increase in the sourcing of biologics and generic manufacturing. The market revenues are forecast to reach approximate value of $44 billion by 2015. The market is forecast to grow at a CAGR of 11%.
CMOs Have Started Providing End-to-End Solutions for Pharmaceutical Manufacturers Expanding Market Potential
Earlier CMOs restricted their businesses only to the key production aspects of the pharmaceutical production chain. This was because Pharma manufacturers seldom approached CMOs for services other than primary and secondary manufacturing.
CMO Market, Global, CMOs Providing Overall Pharmaceutical Solutions, 2008
Presently the CMO market is witnessing stiff competition with numerous CMOs emerging within a short time span. In order to remain dominant within the market, Tier 1 CMOs have started offering complete Pharma solutions to clients. This implies that these CMOs assist Pharma manufacturer’s right from clinical trials to commercial manufacturing, logistics, packaging, and even marketing assistance. Subsequently Pharma manufacturers seem to increasingly accept this business model and are increasingly outsourcing their production in an effort to save cost and continue production.
Initially this concept of providing total Pharma solutions was present only within the US and certain European countries. Over the past couple of years countries like India, Korea and China have started adopting the same business model. Due to vast difference is the production and labor costs, Manufacturers are shifting their focus to Asian CMOs. It is seen that overall costs for drug manufacturing in India for example, is up to 50% cheaper than in Western countries. Cost savings in this scale present a golden opportunity for Western Pharma manufacturers to outsource to Asian CMOs. Apart from this CMOs are also applying the strategy of integration. Over the past couple of years CMOs are integrating their service portfolios to offer complete solutions to Pharma manufacturers. Through these kinds of relationships, both the CMOs can pursue large-scale business opportunities using each others’ facilities.
- Piramal Healthcare
- Jubilant Organosys
- Royal DSM N.V.
- Boehringer Ingelheim
A sample for this product is available. Please Login/Register to download this sample.